ClinicalTrials.gov
ClinicalTrials.gov Menu

Sorafenib Plus Capecitabine Efficacy Assessment in Patients With Advanced Pre-treated Colorectal Cancer (SoMore)

The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Read our disclaimer for details.
ClinicalTrials.gov Identifier: NCT01290926
Recruitment Status : Completed
First Posted : February 7, 2011
Last Update Posted : February 24, 2016
Sponsor:
Collaborators:
Erasme University Hospital
INDC Entité Jolimontoise
Centre Hospitalier Chretien
Universiteit Antwerpen
Cliniques universitaires Saint-Luc- Université Catholique de Louvain
Hospital Ambroise Paré Paris
Information provided by (Responsible Party):
Jules Bordet Institute

Brief Summary:
Prospective non-randomized phase II study assessing the activity of the Capecitabine-Sorafenib combination by estimating overall survival of the study population at a fixed time point (6 months) and, as an exploratory analysis the overall survival of metabolic responders versus non-responders.

Condition or disease Intervention/treatment Phase
Colorectal Cancer Drug: chemotherapy Phase 2

  Show Detailed Description

Study Type : Interventional  (Clinical Trial)
Actual Enrollment : 97 participants
Intervention Model: Single Group Assignment
Masking: None (Open Label)
Primary Purpose: Treatment
Official Title: Sorafenib Plus Capecitabine Efficacy Assessment in Patients With Advanced Pre-treated Colorectal Cancer
Study Start Date : February 2011
Actual Primary Completion Date : January 2016
Actual Study Completion Date : January 2016

Resource links provided by the National Library of Medicine


Arm Intervention/treatment
Experimental: Capecitabine & Sorafenib
Sorafenib 200mg in the morning,400mg in the evening; escalation to 400mg twice daily after 1 cycle, Oral, Continuous dosing Capecitabine 850mg/m2 twice daily, Oral Days 1-14, weeks 1-2
Drug: chemotherapy
sorafenib 600mg/day capecitabine 1250 mg/m²/day
Other Names:
  • Xeloda
  • Nexavar




Primary Outcome Measures :
  1. Overall survival at 6 months fixed endpoint [ Time Frame: 6 months ]

    The 2 primary co-endpoints are :

    1. To obtain a preliminary assessment about the activity of the combination by estimating overall survival of the study population at a fixed time point (6 months)
    2. To compare as an exploratory analysis the overall survival of metabolic responders versus non-responders.


Secondary Outcome Measures :
  1. To estimate the Progression Free Survival (PFS) distribution of the study population [ Time Frame: 12 months ]
  2. To determine the objective response rate of the study population as assessed by standard imaging [ Time Frame: 12 months ]
  3. To describe the adverse reactions associated with the study regimen in the study population. [ Time Frame: 12 months ]
  4. To determine the correlation of early metabolic response, as assessed by FDG-PET/CT immediately before the first and the second cycles of treatment with the study regimen, with overall survival, progression-free survival, and response. [ Time Frame: 12 months ]
  5. To determine the correlation of growth modulation index (GMI), defined as the time to progression under the study regimen over the time to progression un-der the latest prior regimen administered to the patient, with overall survival and progression-free [ Time Frame: 12 months ]


Information from the National Library of Medicine

Choosing to participate in a study is an important personal decision. Talk with your doctor and family members or friends about deciding to join a study. To learn more about this study, you or your doctor may contact the study research staff using the contacts provided below. For general information, Learn About Clinical Studies.


Ages Eligible for Study:   18 Years and older   (Adult, Older Adult)
Sexes Eligible for Study:   All
Accepts Healthy Volunteers:   No
Criteria

Inclusion Criteria:

  • Participants must have histologically confirmed colorectal cancer that is metastatic or unresectable and for which standard curative or palliative measures do not exist or are no longer effective.
  • All standard chemotherapy agents (fluoropyrimidines, irinotecan, and oxaliplatin) and monoclonal antibodies (bevacizumab, cetuximab, and panitumumab) are allowed as administered therapy before study entry. No more than two lines of treatment for metastatic or recurrent disease are allowed, except for patients with KRAS-wt tumors, for which third line with anti-EGFR agents is allowed.
  • Age over 18 years.
  • Life expectancy of greater than 12 weeks.
  • ECOG performance status ≤ 1.
  • Participants must have normal organ and marrow function as defined below:
  • Leukocytes > 3,000/mcL
  • Absolute neutrophil count > 1,500/mcL
  • Platelets > 100,000/mcL
  • total bilirubin within 2 × normal institutional limits
  • AST/ALT/PAKL levels < 5 × institutional upper limit of normal
  • creatinine within 2 × normal institutional limits or creatinine clearance > 35mL/min
  • Women of child-bearing potential and men must agree to use adequate contraception (hormonal or barrier method of birth control, abstinence) prior to study entry and for the duration of study participation. Should a woman become pregnant or suspect she is pregnant while participating in this study, she should inform her treating physician immediately.
  • Ability to understand and the willingness to sign a written informed consent document.

Exclusion Criteria:

Participants who exhibit any of the following conditions at screening will not be eligible for admission into the study.

  • Participants who have had chemotherapy or radiotherapy within 4 weeks prior to entering the study or those who have not recovered from adverse events due to agents administered more than 4 weeks earlier.
  • Participants may not be receiving any other experimental agents.
  • Participants with known brain metastases should be excluded from this clinical trial because of their poor prognosis and because they often develop progressive neurologic dysfunction that would confound the evaluation of neurologic and other adverse events.
  • History of allergic reactions attributed to compounds of similar chemical or biologic composition to sorafenib or capecitabine.
  • Bleeding diathesis, history of cardiovascular ischemic disease or cerebrovascular incident within the last six months, or major surgery within four weeks.
  • Uncontrolled concurrent illness including, but not limited to ongoing or active infection, symptomatic congestive heart failure, unstable angina pectoris, cardiac arrhythmia, or psychiatric illness/social situations that would limit compliance with study requirements.
  • Pregnant women are excluded from this study because sorafenib and capecitabine are antitumor agents with the potential for teratogenic or abortifacient effects. Because there is an unknown but potential risk of adverse events in nursing infants secondary to treatment of the mother with sorafenib or capecitabine, breastfeeding should be discontinued if the mother is treated with sorafenib or capecitabine. These potential risks may also apply to other agents used in this study.
  • Uncontrolled Diabetes
  • FDG PET/CT negative lesions or non metabolically assessable lesions (to small <2cm) at the base line FDG PET/CT
  • Individuals with a history of a different malignancy are ineligible except for the following circumstances. Individuals with a history of other malignancies are eligible if they have been disease-free for at least 5 years and are deemed by the investigator to be at low risk for recurrence of that malignancy. Individuals with the following cancers are eligible if diagnosed and treated within the past 5 years: cervical cancer in situ, and basal cell or squamous cell carcinoma of the skin.

Information from the National Library of Medicine

To learn more about this study, you or your doctor may contact the study research staff using the contact information provided by the sponsor.

Please refer to this study by its ClinicalTrials.gov identifier (NCT number): NCT01290926


Locations
Belgium
Cliniques Universitaires Saint Luc
Woluwe Saint Lambert, Bruxelles, Belgium, 1200
Universiteit Ziekenhuis Antwerpen
Antwerpen, Belgium
Institut Jules Bordet
Brussels, Belgium, 1000
Hopital Erasme
Brussels, Belgium, 1070
Entité Jolimontoise
La Louviere, Belgium
Hopitaux St Joseph
Liege, Belgium, 4000
CHU Ambroise Paré
Mons, Belgium, 7000
Sponsors and Collaborators
Jules Bordet Institute
Erasme University Hospital
INDC Entité Jolimontoise
Centre Hospitalier Chretien
Universiteit Antwerpen
Cliniques universitaires Saint-Luc- Université Catholique de Louvain
Hospital Ambroise Paré Paris
Investigators
Principal Investigator: Alain Hendlisz, MD Jules Bordet Institute

Publications automatically indexed to this study by ClinicalTrials.gov Identifier (NCT Number):
Responsible Party: Jules Bordet Institute
ClinicalTrials.gov Identifier: NCT01290926     History of Changes
Other Study ID Numbers: EudraCT 2010-023695-91
First Posted: February 7, 2011    Key Record Dates
Last Update Posted: February 24, 2016
Last Verified: February 2016

Keywords provided by Jules Bordet Institute:
advanced chemorefractory colorectal cancer
sorafenib
capecitabine
FDG-PET
early metabolic response

Additional relevant MeSH terms:
Colorectal Neoplasms
Intestinal Neoplasms
Gastrointestinal Neoplasms
Digestive System Neoplasms
Neoplasms by Site
Neoplasms
Digestive System Diseases
Gastrointestinal Diseases
Colonic Diseases
Intestinal Diseases
Rectal Diseases
Capecitabine
Sorafenib
Niacinamide
Antimetabolites, Antineoplastic
Antimetabolites
Molecular Mechanisms of Pharmacological Action
Antineoplastic Agents
Protein Kinase Inhibitors
Enzyme Inhibitors
Vitamin B Complex
Vitamins
Micronutrients
Growth Substances
Physiological Effects of Drugs